Title

Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Authors

Lisanne C. Verbruggen, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Yuehan Wang, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Saro H. Armenian, Department of Population Sciences, City of Hope National Medical Center, Duarte, California, USA.
Matthew J. Ehrhardt, Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Helena J. van der Pal, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Elvira C. van Dalen, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Jorrit W. van As, Cochrane Childhood Cancer, Amsterdam, the Netherlands.
Edit Bardi, St Anna Childrens Hospital, Vienna, Austria.
Katja Baust, Department for Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.
Claire Berger, Department for Pediatric Hematology and Oncology CHU Nord, University Hospital Saint-Etienne, Saint-Priest en Jarez, France.
Elio Castagnola, Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Katie A. Devine, Rutgers Cancer Institute of New Jersey, The State University of New Jersey, New Brunswick, New Jersey, USA.
Judith Gebauer, Institute for Endocrinology and Diabetes, University of Luebeck, Ratzeburger Allee 160, Luebeck, 23562, Germany.
Jordan Gilleland Marchak, Emory University School of Medicine, Aflac Cancer and Blood Disorders Center, Atlanta, Georgia, USA.
Adam W. Glaser, Department of Paediatric Oncology, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Medical Research, University of Leeds, Leeds, LS2 9JT, UK.
Andreas H. Groll, Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University Children's Hospital, Münster, Germany.
Gabrielle M. Haeusler, NHMRC National Centre for Infections in Cancer, Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Jaap den Hartogh, Dutch Childhood Cancer Parent Organization VOKK Netherlands, Department VOX Survivors, Nieuwegein, the Netherlands.
Riccardo Haupt, Epidemiology and Biostatistics Unit and DOPO clinic IRCCS Istituto Giannina Gaslini, Genova, Italy.
Lars Hjorth, Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Pediatrics, Lund, Sweden.
Miho Kato, Department of Pediatric Hematology/Oncology, Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Okinawa, Japan.
Tomáš Kepák, University Hospital Brno and St. Anna University Hospital/ICRC, Masaryk University, Brno, Czech Republic.
Maria M. Koopman, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Thorsten Langer, University Hospital for Children and Adolescents, Pediatric Oncology and Hematology, Ratzeburger Allee 160, Luebeck, 23562, Germany.
Miho Maeda, Department of Pediatrics, Nippon Medical School, Tokyo, Japan.
Gisela Michel, Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
Monica Muraca, Epidemiology and Biostatistics Unit and DOPO Clinic IRCCS Istituto Giannina Gaslini, Genova, Italy.
Paul C. Nathan, The Hospital for Sick Children, Toronto, Canada.
Selina R. van den Oever, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Vesna Pavasovic, Department of Malignant Haematology, Great Ormond Street Hospital for Children NHS Trust, London, UK.
Satomi Sato, St. Luke's International University, Tokyo, Japan.
Fiona Schulte, Department of Oncology, Division of Psychosocial Oncology, University of Calgary, Calgary, AB, Canada.
Lillian Sung, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.

Abstract

Childhood, adolescent, and young adult (CAYA) cancer survivors may be at risk for a severe course of COVID-19. Little is known about the clinical course of COVID-19 in CAYA cancer survivors, or if additional preventive measures are warranted. We established a working group within the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) to summarize existing evidence and worldwide recommendations regarding evidence about factors/conditions associated with risk for a severe course of COVID-19 in CAYA cancer survivors, and to develop a consensus statement to provide guidance for healthcare practitioners and CAYA cancer survivors regarding COVID-19.

Publication Title

Pediatric blood & cancer

Share

COinS